Yubo International Biotech is a China-based biopharmaceutical company engaged in the research, development and commercialization of novel therapeutics for unmet medical needs. Since its inception, the company has focused on leveraging advanced molecular biology and biotechnology platforms to create a diversified pipeline of drug candidates, with particular emphasis on oncology, immunology and metabolic disorders. Yubo’s core capabilities encompass small molecule discovery, monoclonal antibody engineering and gene therapy, supported by state-of-the-art research facilities in both Beijing and Shanghai.
The company’s primary activities include preclinical and clinical development of targeted therapies, strategic partnerships with academic institutions and contract research services for third-party clients. Yubo’s most advanced programs center on next-generation cancer immunotherapies designed to improve specificity and reduce off-target effects, as well as enzyme replacement treatments for rare metabolic conditions. In addition, the organization provides custom biologics manufacturing and process development solutions to pharmaceutical and biotech partners seeking scalable production capabilities.
With a global outlook, Yubo International Biotech maintains collaborative alliances in North America, Europe and Southeast Asia. These alliances facilitate access to international regulatory expertise and global clinical trial networks, enabling the company to advance its lead candidates through pivotal studies. Yubo’s contract development and manufacturing arm also serves customers across multiple continents, offering end-to-end support from cell line development to commercial-scale bioreactor operations.
Leadership at Yubo International Biotech comprises seasoned executives with combined experience at leading multinational pharmaceutical firms and research institutions. The board includes experts in translational medicine, regulatory affairs and business strategy, while the executive team is led by a president with a track record of guiding early-stage programs through regulatory approval. This blend of scientific acumen and commercial insight underpins Yubo’s mission to bring differentiated biologic and small molecule therapies to patients worldwide.
AI Generated. May Contain Errors.
